2026-04-28T12:43:25Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/75592023-04-18T12:48:15Zcom_10259_3924com_10259_5086com_10259_2604col_10259_3925
Espona Fiedler, Margarita
57f3f289-913c-4bdb-be4d-cf031afb4f95
600
Manuel Manresa, Pilar
0e8b3cef-7ea1-44a8-af01-7b49c8f0e385
600
Benítez-García, Cristina
154f3305-d2b6-41b6-b586-95950e57e92b
600
Fontova Pale, Pere
766
600
0000-0002-1352-3084
Quesada Pato, Roberto
458
600
0000-0003-2764-7157
Soto Cerrato, Vanessa
346bb3c7-0c69-4d62-9045-26b0b8d37a51
600
Pérez Tomás, Ricardo
3306d7a2-706a-47ab-8490-869a1b191c58
600
2023-03-20T08:26:03Z
2023-03-20T08:26:03Z
2022-12
http://hdl.handle.net/10259/7559
10.3390/pharmaceutics15010097
1999-4923
Metastasis is the primary cause of death in cancer patients. Many current chemotherapeutic
agents only show cytotoxic, but not antimetastatic properties. This leads to a reduction in tumor
size, but allows cancer cells to disseminate, which ultimately causes patient death. Therefore, novel
anticancer compounds with both effects need to be developed. In this work, we analyze the antimetastatic properties of prodigiosin and obatoclax (GX15-070), anticancer drugs of the Prodiginines
(PGs) family. We studied PGs’ effects on cellular adhesion and morphology in the human primary
and metastatic melanoma cell lines, SK-MEL-28 and SK-MEL-5, and in the murine melanoma cell
line, B16F10A. Cell adhesion sharply decreased in the treated cells, and this was accompanied by a
reduction in filopodia protrusions and a significant decrease in the number of focal-adhesion structures. Moreover, cell migration was assessed through the wound-healing assay and cell motility was
severely inhibited after 24 h of treatment. To elucidate the molecular mechanisms involved, changes
in metastasis-related genes were analyzed through a gene-expression array. Key genes related to
cellular invasion, migration and chemoresistance were significantly down-regulated. Finally, an
in vivo model of melanoma-induced lung metastasis was established and significant differences in
lung tumors were observed in the obatoclax-treated mice. Altogether, these results describe, in depth,
PGs’ cellular antimetastatic effects and identify in vivo antimetastatic properties of Obatoclax.
This research has been funded by Instituto de Salud Carlos III (Grants PI18/00441; FIS PI10/00338) (Co-funded by European Regional Development Fund. ERDF, a way to build Europe).
application/pdf
eng
MDPI
Pharmaceutics. 2022, V. 15, n. 1, 97
https://doi.org/10.3390/pharmaceutics15010097
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI18%2F00441/ES/EVALUACION TERAPEUTICA PRECLINICA EN CANCER DE PULMON DE INHIBIDORES DE SURVIVINA MEDIANTE LA UTILIZACION DE FORMULACIONES NANOENCAPSULADAS Y TERAPIAS COMBINADAS/
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI10%2F00338/ES/
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
Metastasis
Obatoclax
Prodigiosin
Prodiginines
BH3-mimetic
Melanoma
Migration
Química orgánica
Salud
Medicina
Chemistry, Organic
Health
Medicine
Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Pharmaceutics
15
1
THUMBNAIL
Espona-pharmaceutics_2022.pdf.jpg
Espona-pharmaceutics_2022.pdf.jpg
IM Thumbnail
image/jpeg
3403
https://riubu.ubu.es/bitstream/10259/7559/4/Espona-pharmaceutics_2022.pdf.jpg
b19da31998d967953bd937de756f06fe
MD5
4
LICENSE
license.txt
license.txt
text/plain; charset=utf-8
999
https://riubu.ubu.es/bitstream/10259/7559/3/license.txt
b295bcbce42e2caabeb0c623d3860c06
MD5
3
CC-LICENSE
license_rdf
license_rdf
application/rdf+xml; charset=utf-8
908
https://riubu.ubu.es/bitstream/10259/7559/2/license_rdf
0175ea4a2d4caec4bbcc37e300941108
MD5
2
ORIGINAL
Espona-pharmaceutics_2022.pdf
Espona-pharmaceutics_2022.pdf
application/pdf
3677884
https://riubu.ubu.es/bitstream/10259/7559/1/Espona-pharmaceutics_2022.pdf
ee80b274659ee3ada8d64ba32c1b4b37
MD5
1
10259/7559
oai:riubu.ubu.es:10259/7559
2023-04-18 14:48:15.245
Repositorio Institucional de la Universidad de Burgos
bubrep@ubu.es
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